In Vivo Delivery Systems for Therapeutic Genome Editing
AbstractTherapeutic genome editing technology has been widely used as a powerful tool for directly correcting genetic mutations in target pathological tissues and cells to cure of diseases. The modification of specific genomic sequences can be achieved by utilizing programmable nucleases, such as Meganucleases, zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and the clustered regularly-interspaced short palindromic repeat-associated nuclease Cas9 (CRISPR/Cas9). However, given the properties, such as large size, negative charge, low membrane penetrating ability, as well as weak tolerance for serum, and low endosomal escape, of these nucleases genome editing cannot be successfully applied unless in vivo delivery of related programmable nucleases into target organisms or cells is achieved. Here, we look back at delivery strategies having been used in the in vivo delivery of three main genome editing nucleases, followed by methodologies currently undergoing testing in clinical trials, and potential delivery strategies provided by analyzing characteristics of nucleases and commonly used vectors. View Full-Text
Share & Cite This Article
Wang, L.; Li, F.; Dang, L.; Liang, C.; Wang, C.; He, B.; Liu, J.; Li, D.; Wu, X.; Xu, X.; Lu, A.; Zhang, G. In Vivo Delivery Systems for Therapeutic Genome Editing. Int. J. Mol. Sci. 2016, 17, 626.
Wang L, Li F, Dang L, Liang C, Wang C, He B, Liu J, Li D, Wu X, Xu X, Lu A, Zhang G. In Vivo Delivery Systems for Therapeutic Genome Editing. International Journal of Molecular Sciences. 2016; 17(5):626.Chicago/Turabian Style
Wang, Luyao; Li, Fangfei; Dang, Lei; Liang, Chao; Wang, Chao; He, Bing; Liu, Jin; Li, Defang; Wu, Xiaohao; Xu, Xuegong; Lu, Aiping; Zhang, Ge. 2016. "In Vivo Delivery Systems for Therapeutic Genome Editing." Int. J. Mol. Sci. 17, no. 5: 626.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.